5T4 binding polypeptides and uses thereof
Described herein are polypeptides that bind to 5T4 useful for cancer therapy. Further disclosed herein are polypeptides that bind to 5T4 that are conjugated to a chelating agent or a radionuclide complex thereof.
1 . A polypeptide that binds 5T4, wherein the polypeptide comprises an immunoglobulin variable domain comprising:
(i) a complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 13; a complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 14; and a complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 15;
(ii) a complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 16; a complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 17; and a complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 18;
(iii) a complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 19; a complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 20; and a complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 21; or
(iv) a complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 22; a complementarity determining region 2 (CDR2) comprising the amino acid sequence of SEQ ID NO: 23; and a complementarity determining region 3 (CDR3) comprising the amino acid sequence of SEQ ID NO: 24.
2 . The polypeptide of claim 1 , wherein the immunoglobulin variable domain comprises at least 80% sequence identity to SEQ ID NOs: 27-29.
3 . The polypeptide of claim 1 , wherein the immunoglobulin variable domain comprises the sequence of any one of SEQ ID NOs: 27-29.
4 . The polypeptide of claim 1 , wherein the polypeptide comprises an Fc domain and/or an immunoglobulin hinge region.
5 . The polypeptide of claim 4 , wherein the Fc domain and/or the immunoglobulin hinge region comprises an amino acid sequence having at least about 80% sequence identity to SEQ ID NO: 47.
6 . The polypeptide of claim 4 , wherein the Fc domain and/or the immunoglobulin hinge region comprises an amino acid sequence set forth in SEQ ID NO: 47.
7 . The polypeptide of claim 4 , wherein the Fc domain is an IgG1 Fc domain.
8 . The polypeptide of claim 4 , wherein the Fc domain comprises one or more amino acid residue alterations that reduce effector function of the polypeptide and/or one or more amino acid residue alterations that alter binding of the polypeptide to a neonatal Fe receptor (FcRn), thereby reducing the serum half-life of the polypeptide.
9 . The polypeptide of claim 8 , wherein the one or more amino acid residue alterations that reduce effector function comprises L234A, L235E, G237A, A330S, and P331S per EU numbering.
10 . The polypeptide of claim 8 , wherein the one or more amino acid residues that alter binding of the polypeptide to the neonatal Fc receptor (FcRn) comprise H310A, H310D, H310E, H310Q, H435A, H435Q, and combinations thereof, per EU numbering.
11 . The polypeptide of claim 8 , wherein the one or more amino acid residues that alter binding of the polypeptide to the neonatal Fe receptor (FcRn) comprise H310A.
12 . A method of making a polypeptide that binds 5T4, comprising culturing, in a culture medium, a host cell comprising a nucleic acid or a plurality of nucleic acids encoding the polypeptide of claim 1 under conditions sufficient to express and secrete the polypeptide and recovering the polypeptide from the host cell or the culture medium thereof.
13 . The polypeptide of claim 8 , wherein the one or more amino acid residues that alter binding of the polypeptide to the neonatal Fe receptor (FcRn) comprise H435Q.
14 . The polypeptide of claim 1 , wherein the immunoglobulin variable domain is an immunoglobulin heavy chain variable domain, and wherein the immunoglobulin heavy chain variable domain is a VHH.
15 . A dimer comprising two polypeptides according to claim 1 .
16 . An immunoconjugate comprising the polypeptide of claim 1 conjugated to a chelating agent or a radionuclide complex thereof.
17 . The immunoconjugate of claim 16 , wherein the immunoconjugate comprises Formula (II) or a pharmaceutically acceptable salt thereof:
wherein,
R 1 is a chelating agent or a radionuclide complex thereof;
X 1 is absent, —O—, —S—, —S(═O)—, —S(═O) 2 —, —NR a —, —C(═O)—, —NR a C(═O)—, —C(═O)NR a —, —(C 1 -C 6 alkylene)-X 2 —, or —(C 4 -C 20 polyethylene glycol)-X 2 —;
X 2 is absent, —C(═O)—, —NR a C(═O)—, —C(═O)NR a —, or —C(═O)X 4 —;
each R a is independently selected from hydrogen and C 1 -C 4 alkyl;
X 4 is —NR a — or —NR a S(═O) 2 —;
L is an optional linker;
—NH—R 3 is the polypeptide; and
v is 1, 2, 3, or 4.
18 . The immunoconjugate of claim 17 , wherein:
v is 1; and
19 . A nucleic acid encoding the polypeptide of claim 1 .
20 . A host cell comprising the nucleic acid of claim 19 .
21 . The immunoconjugate of claim 17 , prepared by conjugating the polypeptide (R 3 ) of claim 1 to the following compound:
wherein TFP is tetrafluorophenyl.
22 . The immunoconjugate of claim 17 , wherein:
v is 1;
R 1 is
and
23 . The immunoconjugate of claim 17 , prepared by conjugating the polypeptide (R 3 ) of claim 1 to a compound of Formula (VIb):
wherein:
v is 1;
R 1 is
and
R 2 is
24 . The immunoconjugate of claim 16 , wherein the chelating agent is coupled to the g polypeptide by a linker.
25 . The immunoconjugate of claim 16 , wherein the chelating agent further comprises a radionuclide.
26 . The immunoconjugate of claim 25 , wherein the radionuclide is a diagnostic or a therapeutic radionuclide.
27 . The immunoconjugate of claim 25 , wherein the radionuclide is an Auger electron-emitting radionuclide, an α-emitting radionuclide, a β-emitting radionuclide, or a γ-emitting radionuclide.
28 . The immunoconjugate of claim 25 , wherein the radionuclide is an α-emitting radionuclide.
29 . The immunoconjugate of claim 25 , wherein the radionuclide is 225-actinium ( 225 Ac).
30 . The immunoconjugate of claim 25 , wherein the radionuclide is 111-indium ( 111 In).
31 . A method of targeting a radionuclide to a 5T4 expressing cancer or tumor cell of an individual, the method comprising administering to the individual the immunoconjugate of claim 16 .
32 . A method of treating a cancer or tumor of an individual, the method comprising administering to the individual an effective amount of the polypeptide of claim 1 or the immunoconjugate of claim 16 , thereby treating the cancer or the tumor of the individual.
33 . A method of imaging a cancer or tumor of an individual, the method comprising administering to the individual an effective amount of the immunoconjugate of claim 16 , thereby targeting the radionuclide to a 5T4-expressing cancer or tumor cell of the individual, and imaging the 5T4-expressing cancer or tumor cell of the individual.
34 . The method of claim 32 , wherein the cancer or tumor of the individual expresses 5T4.
35 . The method of claim 32 , wherein the cancer or tumor of the individual is a colorectal cancer or tumor, a cervical cancer or tumor, a pancreatic cancer or tumor, a non-small cell lung (NSCLC) cancer or tumor, or a head and neck squamous cell cancer or tumor.
36 . A method of making the immunoconjugate of claim 16 , comprising complexing a radionuclide to the chelating agent.